FIELD: genetic engineering.
SUBSTANCE: invention relates to genetic engineering. Described is a DNA vaccine against the SARS-CoV-2 virus based on the gene therapy DNA vector GDTT1.8NAS12, consisting of a composition of gene therapy DNA vectors GDTT1.8NAS12-S, GDTT1.8NAS12-M and GDTT1.8NAS12-N encoding immunogenic epitopes of proteins S, M, N of the SARS-CoV-2 virus, respectively, and the gene therapy DNA vector GDTT1.8NAS12-S has the nucleotide sequence SEQ ID No. 1, the gene therapy DNA vector GDTT1.8NAS12 has the nucleotide sequence SEQ ID No. 2, the gene therapy DNA vector GDTT1.8NAS12 has the nucleotide sequence SEQ ID No. 3, in this case, each of the nucleotide sequences SEQ ID No. 1, SEQ ID No.2 and SEQ ID No. 3 was cloned into the gene therapy DNA vector GDTT1.8NAS12. The method for obtaining this vaccine and the method for its production on an industrial scale are also presented.
EFFECT: invention expands the arsenal of means for human immunization against the SARS-CoV-2 virus.
6 cl, 5 dwg, 11 ex
